Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells

Biochemical Pharmacology

Volumn 82, Issue 9, 2011, Pages 1090-1099

  Joshi, Jayashree P ^a   Brown, Nicole E ^b   Griner, Samantha E ^a   Nahta, Rita ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Breast cancer; erbB2; Herceptin; Lapatinib; Resistance; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GROWTH DIFFERENTIATION FACTOR 15; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECOMBINANT GROWTH DIFFERENTIATION FACTOR 15; RECOMBINANT PROTEIN; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, ERBB-2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 80053998053     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.07.082     Document Type: Article

References (29)

1. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
2. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, and L. Dantis Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 1996 737 744
3. M.A. Cobleigh, C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, and L. Fehrenbacher Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648 (Pubitemid 29415219)
4. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, and A. Bajamonde Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
5. F.J. Esteva, V. Valero, D. Booser, L.T. Guerra, J.L. Murray, and L. Pusztai Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 1800 1808 (Pubitemid 34273269)
6. R. Nahta, T. Takahashi, N.T. Ueno, M.C. Hung, and F.J. Esteva P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 2004 3981 3986 (Pubitemid 38697313)
7. Y. Nagata, K.H. Lan, X. Zhou, M. Tan, F.J. Esteva, and A.A. Sahin PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127 (Pubitemid 39485684)
8. K. Berns, H.M. Horlings, B.T. Hennessy, M. Madiredjo, E.M. Hijmans, and K. Beelen A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 2007 395 402 (Pubitemid 47539306)
9. T. Ozbay, D.L. Durden, T. Liu, R.M. O'Regan, and R. Nahta In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells Cancer Chemother Pharmacol 65 2010 697 706
10. Y. Lu, X. Zi, Y. Zhao, D. Mascarenhas, and M. Pollak Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 2001 1852 1857 (Pubitemid 34048651)
11. R. Nahta, L.X. Yuan, B. Zhang, R. Kobayashi, and F.J. Esteva Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 2005 11118 11128 (Pubitemid 41713383)
12. M.R. Bootcov, A.R. Bauskin, S.M. Valenzuela, A.G. Moore, M. Bansal, and X.Y. He MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily Proc Natl Acad Sci USA 94 1997 11514 11519 (Pubitemid 27451030)
13. M. Mimeault, and S.K. Batra Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer J Cell Physiol 224 2010 626 635
14. A.C. Staff, A.J. Bock, C. Becker, T. Kempf, K.C. Wollert, and B. Davidson Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer Gynecol Oncol 118 2010 237 243
15. P. Roth, M. Junker, I. Tritschler, M. Mittelbronn, Y. Dombrowski, and S.N. Breit GDF-15 contributes to proliferation and immune escape of malignant gliomas Clin Cancer Res 16 2010 3851 3859
16. D.A. Brown, R.L. Ward, P. Buckhaults, K. Bälter, H.O. Adami, and S.L. Zheng MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma Clin Cancer Res 9 2003 2642 2650 (Pubitemid 36842108)
17. J.B. Welsh, L.M. Sapinoso, S.G. Kern, D.A. Brown, T. Liu, and A.R. Bauskin Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum Proc Natl Acad Sci USA 100 2003 3410 3415 (Pubitemid 36356597)
18. K.K. Kim, J.J. Lee, Y. Yang, K.H. You, and J.H. Lee Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of HER2 in human breast and gastric cancer cells Carcinogenesis 29 2008 704 712 (Pubitemid 351494157)
19. Y.J. Park, H. Lee, and J.H. Lee Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells BMB Rep 43 2010 91 96
20. D.L. Rowe, T. Ozbay, L.M. Bender, and R. Nahta Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer Mol Cancer Ther 7 2008 1900 1908
21. Tusher, Tibshirani, and Chu Significance analysis of microarrays applied to the ionizing radiation response Proc Natl Acad Sci USA 98 2001 5116 5121 (Pubitemid 32397092)
22. L. Gu, S. Waliany, and S.E. Kane Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance PLoS ONE 4 2009 e6220
23. M. Böttner, M. Laaff, B. Schechinger, G. Rappold, K. Unsicker, and C. Suter-Crazzolara Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1) Gene 237 1999 105 111 (Pubitemid 29406202)
24. M. Osada, H.L. Park, M.J. Park, J.W. Liu, G. Wu, and B. Trink A p53-type response element in the GDF15 promoter confers high specificity for p53 activation Biochem Biophys Res Commun 354 2007 913 918 (Pubitemid 46216219)
25. S.J. Baek, J.S. Kim, J.B. Nixon, R.P. DiAugustine, and T.E. Eling Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1 J Biol Chem 279 2004 6883 6892 (Pubitemid 38248831)
26. T. Ichikawa, Y. Suenaga, T. Koda, T. Ozaki, and A. Nakagawara TAp63-dependent induction of growth differentiation factor 15 (GDF15) plays a critical role in the regulation of keratinocyte differentiation Oncogene 27 2008 409 420
27. Y.L. Chen, P.C. Lin, S.P. Chen, C.C. Lin, N.M. Tsai, and Y.L. Cheng Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase revealed a isochaihulactone-triggered apoptotic pathway in human lung cancer A549 cells J Pharmacol Exp Ther 323 2007 746 756
28. K. Yamaguchi, S.H. Lee, T.E. Eling, and S.J. Baek Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway J Biol Chem 279 2004 49617 49623 (Pubitemid 39577764)
29. Y. Kataoka, T. Mukohara, H. Shimada, N. Saijo, M. Hirai, and H. Minami Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines Ann Oncol 21 2010 255 262